Comparison of haematological recovery kinetics after myeloablative therapy between sibling allogeneic bone marrow and peripheral blood progenitor cell transplantation in the same adult acute lymphoblastic leukaemia patient.
Stockschläder
M
M
Hassan
H T
HT
Krüger
W
W
Kabisch
H
H
Zander
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001853:Bone Marrow / Q000502:physiology*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009679:Nuclear Family; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
D003561:Cytarabine; D005047:Etoposide; D003520:Cyclophosphamide; D008942:Mitoxantrone; D002066:Busulfan; D015255:Idarubicin